Skip to main content

Table 5 Proportions of decisions at the end of the trial in seven scenarios when K=3

From: Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome

    Subset A Subset B Subset C
Scenarios Pattern Go with EP ∗ Go with SP (efficacy/ interaction) ∗ nA Go with SP (efficacy/ interaction) ∗ nB Go with SP (efficacy/ interaction) ∗ nC Go with A and B Go with A and C Go with B and C
Scenario 1 1 0.94 0.02 266.55 0.02 266.43 0.02 267.02 0.00 0.00 0.00
  2 0.90 0.02 137.03 0.04 268.99 0.04 393.98 0.00 0.00 0.00
  3 0.87 0.05 474.35 0.06 272.87 0.02 52.78 0.00 0.00 0.00
  4 0.89 0.04 268.64 0.04 394.67 0.02 136.68 0.00 0.00 0.00
  5 0.86 0.06 273.72 0.02 53.72 0.05 472.56 0.00 0.00 0.00
Scenario 2 1 0.87 0.04 265.96 0.04 265.86 0.04 268.18 0.00 0.00 0.00
  2 0.71 0.02 121.46 0.10 269.10 0.16 409.45 0.00 0.00 0.01
  3 0.44 0.31 480.78 0.21 279.86 0.02 39.36 0.02 0.00 0.00
  4 0.71 0.09 268.44 0.16 408.75 0.03 122.81 0.01 0.00 0.00
  5 0.46 0.21 282.57 0.01 39.47 0.30 477.95 0.00 0.01 0.00
Scenario 3 1 0.56 0.00 182.53 0.00 182.83 0.44 434.64 0.00 0.00 0.00
  2 0.09 0.00 48.59 0.00 98.19 0.90 653.22 0.00 0.00 0.00
  3 0.82 0.03 444.14 0.03 247.72 0.13 108.13 0.00 0.00 0.00
  4 0.73 0.01 218.48 0.01 328.03 0.26 253.49 0.00 0.00 0.00
  5 0.01 0.00 78.30 0.00 13.36 0.98 708.34 0.00 0.00 0.00
Scenario 4 1 0.76 0.00 222.18 0.10 289.78 0.09 288.05 0.00 0.00 0.04
  2 0.33 0.00 75.06 0.17 276.00 0.32 448.94 0.00 0.00 0.16
  3 0.46 0.02 342.21 0.50 417.39 0.02 40.39 0.00 0.00 0.00
  4 0.57 0.01 192.46 0.34 485.06 0.04 122.48 0.00 0.00 0.03
  5 0.21 0.02 145.08 0.02 34.79 0.73 620.14 0.00 0.00 0.01
Scenario 5 1 0.68 0.00 204.21 0.02 244.22 0.21 351.56 0.00 0.00 0.09
  2 0.14 0.00 52.01 0.02 183.50 0.54 564.49 0.00 0.00 0.28
  3 0.63 0.02 379.82 0.30 364.59 0.04 55.59 0.00 0.00 0.01
  4 0.68 0.00 206.75 0.13 426.00 0.09 167.25 0.00 0.00 0.08
  5 0.06 0.00 87.94 0.00 17.59 0.91 694.47 0.00 0.00 0.02
Scenario 6 1 0.67 0.01 216.19 0.31 377.23 0.00 206.58 0.00 0.00 0.00
  2 0.59 0.02 106.91 0.39 402.04 0.00 291.05 0.00 0.00 0.00
  3 0.22 0.03 296.85 0.75 476.13 0.00 27.02 0.00 0.00 0.00
  4 0.23 0.02 156.39 0.74 572.35 0.00 71.26 0.00 0.00 0.00
  5 0.84 0.05 263.31 0.11 98.39 0.00 438.31 0.00 0.00 0.00
Scenario 7 1 0.40 0.00 157.15 0.59 490.36 0.00 152.49 0.00 0.00 0.00
  2 0.30 0.00 70.66 0.70 527.77 0.00 201.56 0.00 0.00 0.00
  3 0.06 0.01 182.16 0.93 601.83 0.00 16.00 0.00 0.00 0.00
  4 0.03 0.00 87.41 0.96 671.51 0.00 41.08 0.00 0.00 0.00
  5 0.76 0.03 241.06 0.21 147.67 0.00 411.27 0.00 0.00 0.00
  1. The total sample size is set at n= 800, with πk=1/3 and qA=qB=qC=0.5.
  2. *EP: entire population;
  3. *SP: subpopulation (efficacy/interaction) due to the detection of interaction with efficacy in subset k;
  4. nA,nB and nC are the mean sample size in each subset at the end of the study
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us